SCM
LBRX

Soleus Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Soleus Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$247K – 114
2026
Q1 		$247K Hold
10,000
– – 0.01% 91
2025
Q4 		$223K Sell
10,000
-390,000
-98% -$6.81M 0.01% 92
2025
Q3 		$6.32M Buy
+400,000
New +$6.35M 0.32% 55

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Soleus Capital Management's LBRX Position: Q2 2026 in Review

Soleus Capital Management sold out of LB Pharmaceuticals (LBRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $247K sold.

Soleus Capital Management first reported a position in LBRX in Q3 2025 and held it in 3 quarters. The position peaked at $6.32M in Q3 2025. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Soleus Capital Management reported no remaining LB Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 10,000 LB Pharmaceuticals shares in Q2 2026, an estimated $247K.
  • Soleus Capital Management first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Soleus Capital Management's LB Pharmaceuticals position peaked at $6.32M in Q3 2025.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.